WisPaper
WisPaper
Search
Assistant
Pricing
TrueCite

Does metformin slow the aging process?

Metformin may slow aging by reducing age-related disease risk and improving health markers, but evidence in healthy humans is still uncertain.

Direct answer

Yes, metformin appears to slow some aspects of the aging process, but the evidence is strongest for people with metabolic conditions like type 2 diabetes, not necessarily for healthy individuals. In a large observational study, women with diabetes who took metformin had a 30% lower risk of dying before age 90 compared to those on a different diabetes drug [1]. A rigorous primate study found that metformin reversed brain aging by about 6 years and improved cognitive function [6]. However, recent reviews highlight that many early, promising findings came from flawed studies, and large clinical trials in healthy people are still ongoing [10]. So while metformin shows real potential, it's not yet proven to extend lifespan in healthy humans.

13sources cited

This article was generated with WisPaper-powered search and paper analysis.

How does metformin actually affect the aging process?

Metformin targets several fundamental hallmarks of aging at the cellular level. It reduces chronic low-grade inflammation, lowers oxidative stress, improves how cells handle energy, and even influences how DNA is read and repaired [7][12]. For example, in a 2024 study on male monkeys, metformin activated a key antioxidant pathway called Nrf2, which protected brain cells from damage and preserved cognitive function [6]. It also slowed the monkeys' biological aging clocks—measured through gene activity and DNA markers—by the equivalent of about 6 years in the brain [6].

Metformin also appears to rejuvenate the immune system. In a study of 88 people of different ages, metformin reduced the number of aged, dysfunctional CD8+ T cells (a type of immune cell) and boosted telomerase, an enzyme that helps maintain chromosome ends and is linked to longer cell life [13]. This suggests metformin may help counter immunosenescence—the gradual weakening of the immune system with age.

Does taking metformin actually help people live longer or healthier?

The strongest human evidence comes from studies in people with type 2 diabetes, not healthy individuals. In a 2025 study that mimicked a clinical trial, women with diabetes who started metformin had a 30% lower risk of dying before age 90 compared to those starting a different diabetes drug (sulfonylurea) [1]. That's a significant increase in the chance of reaching exceptional longevity. Another analysis of over 1.4 million people with diabetes found that metformin users had 37% lower odds of developing age-related macular degeneration (AMD), a leading cause of blindness in older adults [2]. A separate case-control study of over 300,000 people confirmed this protective effect, noting it was strongest at low to moderate doses [4].

Metformin also improves quality of life in specific age-related conditions. In a randomized controlled trial of older adults with sarcopenia (age-related muscle loss), those taking metformin for four months showed significant improvements in handgrip strength and overall quality of life scores related to physical and mental health, compared to placebo [3]. The study linked these benefits to reduced gut leakage and lower inflammation [3]. However, a 2025 review warns that many early, influential studies on metformin and longevity had methodological flaws, and that recent replication attempts have been inconsistent [10]. The bottom line: metformin shows real promise for extending healthspan in people with metabolic issues, but we don't yet know if it works the same way in healthy individuals.

Is metformin a magic pill for everyone? What are the limits?

No—metformin's effects on aging are context-dependent, and it may even be counterproductive in some groups. A 2026 perspective paper highlights a 'therapeutic paradox': while metformin helps frail, insulin-resistant older adults by improving metabolism and reducing inflammation, it can actually blunt muscle growth in physically active older adults who are trying to build muscle through resistance exercise [5]. This is because metformin activates AMPK, a pathway that suppresses the muscle-building mTORC1 signal [5]. So for a healthy person lifting weights, metformin might limit the gains.

Sex also matters. In a mouse study, giving metformin to newborn male mice increased their average lifespan by 20%, but in females it slightly shortened lifespan [8]. Another study in female mice prone to breast cancer found metformin extended lifespan by only 8% and reduced tumor size, but the effect was modest [9]. In humans, metformin use was associated with a higher risk of AMD in people with diabetic retinopathy (a complication of diabetes), even though it was protective for those without it [4]. And in a large autopsy study, metformin users had higher odds of small, silent strokes in the brain (subcortical infarcts), though they had less atherosclerosis [11]. These findings mean metformin is not a one-size-fits-all anti-aging drug—its benefits depend on your health status, sex, and even what else you're doing (like exercise).

About These Sources

This answer is built on 13 peer-reviewed studies — published from 2006 to 2026, 6 from 2024 or later, 5 in Q1 journals, collectively cited 375 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 83 papers retrieved from a database of over 500 million.

Sources used in this answer

1

Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation.

In a target trial emulation study of 438 women with type 2 diabetes, metformin initiation was associated with a 30% lower risk of death before age 90 compared to sulfonylurea initiation (hazard ratio 0.70).

2

Association between oral metformin use and the risk of age‐related macular degeneration: A systematic review with meta‐analysis

In a meta-analysis of 9 studies with over 1.4 million people with diabetes, metformin use was associated with 37% lower odds of developing age-related macular degeneration (OR 0.63).

3

Metformin Improves Sarcopenia-Related Quality of Life in Geriatric Adults: A Randomized Controlled Trial.

In a double-blind randomized controlled trial of older adults with sarcopenia, metformin (1.7g twice daily for 4 months) improved handgrip strength and quality of life scores, and reduced markers of inflammation and gut leakage.

4

Association of Metformin Use With Age-Related Macular Degeneration

In a case-control study of over 300,000 people, metformin use was associated with 6% lower odds of developing age-related macular degeneration (OR 0.94), with the strongest benefit at low to moderate doses; however, it was a risk factor in those with diabetic retinopathy (OR 1.07).

5

Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging

This perspective paper argues that metformin's effects on muscle are context-dependent: it may protect against sarcopenia in frail, insulin-resistant individuals but can blunt exercise-induced muscle hypertrophy in healthy older adults due to AMPK activation suppressing mTORC1 signaling.

6

Metformin decelerates aging clock in male monkeys

In a 40-month study of adult male monkeys, metformin slowed biological aging clocks across multiple tissues, reversed brain aging by about 6 years, preserved brain structure, and improved cognitive function, partly through activation of the Nrf2 antioxidant pathway.

7

Anti-aging effects of metformin: impact on signs of aging

This review concludes that metformin can influence all major hallmarks of aging, including genomic instability, telomere erosion, epigenetic changes, mitochondrial dysfunction, and cellular senescence, based on analysis of randomized trials and meta-analyses.

8

Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.

In 129/Sv mice, neonatal metformin exposure increased mean lifespan by 20% in males but slightly decreased it in females, with no significant changes in hormone or metabolic parameters.

9

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

In female HER-2/neu transgenic mice, chronic metformin treatment extended mean lifespan by 8%, reduced the incidence and size of mammary tumors, and slowed age-related metabolic changes.

10

Emerging uncertainty on the anti-aging potential of metformin

This review critically assesses the evidence for metformin as an anti-aging drug, highlighting methodological limitations in early studies and noting that recent replication attempts and clinical trials in non-diabetic individuals have produced inconsistent results, creating uncertainty.

11

Metformin, age-related cognitive decline, and brain pathology

In a study of 3,029 older adults followed for an average of 8 years, metformin users had slower decline in global cognition, episodic memory, and semantic memory, but in autopsied brains (n=1,584) there was no difference in Alzheimer's pathology; metformin users had more subcortical infarcts but less atherosclerosis.

12

Metformin's Mechanisms in Attenuating Hallmarks of Aging and Age-Related Disease

This review summarizes evidence that metformin delays age-related diseases and extends lifespan in model organisms by countering hallmarks of aging, and discusses its translational potential for human aging.

13

The effect of metformin on senescence of T lymphocytes

In a study of 88 people across different ages, metformin reduced the number of senescent CD8+ T cells, increased telomerase concentration, and promoted expression of stemness-related genes while suppressing DNA damage genes, suggesting it can inhibit T cell senescence.